Avalo Therapeutics (STU:C6K0) Ending Cash Position : €101.49 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Avalo Therapeutics Ending Cash Position?

Avalo Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was €101.49 Mil.

Avalo Therapeutics's quarterly Ending Cash Position declined from Sep. 2023 (€9.66 Mil) to Dec. 2023 (€6.92 Mil) but then increased from Dec. 2023 (€6.92 Mil) to Mar. 2024 (€101.49 Mil).

Avalo Therapeutics's annual Ending Cash Position declined from Dec. 2021 (€48.55 Mil) to Dec. 2022 (€12.57 Mil) and declined from Dec. 2022 (€12.57 Mil) to Dec. 2023 (€6.92 Mil).

Avalo Therapeutics Ending Cash Position Historical Data

The historical data trend for Avalo Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Ending Cash Position Chart

Avalo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

3.36

15.71

48.55

12.57

6.92

Avalo Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															15.77	5.96	9.66	6.92	101.49

Avalo Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Avalo Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	12.213	+	-5.292
	=	6.92

Avalo Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	6.942	+	94.545
	=	101.49

Avalo Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Avalo Therapeutics (STU:C6K0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (STU:C6K0) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

AVTX:USA C6K0:Germany

Address

540 Gaither Road, Suite 400, Rockville, MD, USA, 20850

Website

https://www.avalotx.com

Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.

Avalo Therapeutics (STU:C6K0) Headlines

No Headlines